https://www.targetedonc.com/view/durable-response-seen-with-pd-1-plus-braf-mek-inhibitor-combo-in-crc
0
0
2/7/23 at 9:02pm
Organization
Targetedonc.com
Author
Jonah Feldman
Results of a study of dabrefenib, trametinib, and spartalizumab showed efficacy for the combination of a BRAF inhibitor, a MEK inhibitor, and an anti–PD-1 agent in patients with BRAF V600-mutated colorectal cancer.
Create an account
or login to join the discussion